6 completed, 1 active not recruiting. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 6, Active not recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Eirion Therapeutics Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate AI-09 In Participants With Glabellar Lines AI-09 Ready Use Injectable Botulinum Toxin, Vehicle - Glabellar Lines | Phase 2 | Active not recruiting | Eirion Therapeutics Inc. | 68 | 2025-12-03 | 2026-01-07 |
| AI-09 In Subjects With Glabellar Lines, GL-101 AI-09, Vehicle - Glabellar Frown Lines | Phase 1 / Phase 2 | Completed | Eirion Therapeutics Inc. | 96 | 2022-10-03 | 2026-08-31 |
| ET-01 in Subjects With Lateral Canthal Lines, LCL-210 Vehicle, botulinum toxin, Type A - Lateral Canthal Lines, LCL, Crow's Feet | Phase 2 | Completed | Eirion Therapeutics Inc. | 280 | 2021-07-19 | 2024-12-09 |
| ET-01 in Subjects With Lateral Canthal Lines, LCL-209 botulinum toxin, Type A, Vehicle - Lateral Canthal Lines, LCL, Crow's Feet | Phase 2 | Completed | Eirion Therapeutics Inc. | 38 | 2019-02-27 | 2022-07-28 |
| ET-01 in Subjects With Lateral Canthal Lines, LCL-208 botulinum toxin, Type A, Vehicle - Lateral Canthal Lines, Crow's Feet | Phase 2 | Completed | Eirion Therapeutics Inc. | 75 | 2018-10-16 | 2022-08-23 |
| ET-01 in Subjects With Lateral Canthal Lines, LCL-207 Vehicle, botulinum toxin, Type A - Lateral Canthal Lines, Crow's Feet | Phase 2 | Completed | Eirion Therapeutics Inc. | 79 | 2018-08-16 | 2022-04-21 |
| ET-01 in Subjects With Lateral Canthal Lines botulinum toxin, Type A, Vehicle - Lateral Canthal Lines, Crow's Feet | Phase 2 | Completed | Eirion Therapeutics Inc. | 48 | 2017-10-25 | 2022-04-21 |
United States (7)
Klaus Theobald, MD, PhD (2) · Michael Eppolito (1)